Imunon, Inc. (0HUZ.L)
USD 0.83
(-0.97%)
USD 0.83
(-0.97%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 21.03 Million USD | -14.82% |
| 2022 | 24.68 Million USD | 18.68% |
| 2021 | 20.8 Million USD | 14.03% |
| 2020 | 18.24 Million USD | -10.32% |
| 2019 | 20.34 Million USD | -4.08% |
| 2018 | 21.2 Million USD | 15.17% |
| 2017 | 18.41 Million USD | -8.48% |
| 2016 | 20.12 Million USD | -3.79% |
| 2015 | 20.91 Million USD | -15.48% |
| 2014 | 24.74 Million USD | 215.78% |
| 2013 | 7.83 Million USD | -70.16% |
| 2012 | 26.26 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.19 Million USD | -54.61% |
| 2024 Q1 | 4.83 Million USD | -17.06% |
| 2023 Q3 | 3.7 Million USD | -32.31% |
| 2023 FY | 20.31 Million USD | -17.74% |
| 2023 Q4 | 5.82 Million USD | 57.24% |
| 2023 Q1 | 5.49 Million USD | -19.64% |
| 2023 Q2 | 5.47 Million USD | -0.32% |
| 2022 Q3 | 6.12 Million USD | 3.25% |
| 2022 FY | 24.68 Million USD | 18.68% |
| 2022 Q4 | 6.83 Million USD | 11.52% |
| 2022 Q2 | 5.93 Million USD | 2.46% |
| 2022 Q1 | 5.79 Million USD | 6.18% |
| 2021 Q1 | 5.31 Million USD | 164.35% |
| 2021 FY | 20.8 Million USD | 14.03% |
| 2021 Q2 | 5 Million USD | -5.92% |
| 2021 Q4 | 5.45 Million USD | 8.51% |
| 2021 Q3 | 5.02 Million USD | 0.49% |
| 2020 Q3 | 5.26 Million USD | 144.01% |
| 2020 Q4 | 2.01 Million USD | -61.79% |
| 2020 FY | 18.24 Million USD | -10.32% |
| 2020 Q2 | 2.15 Million USD | 14.83% |
| 2020 Q1 | 1.87 Million USD | 10.3% |
| 2019 Q3 | 1.75 Million USD | -22.69% |
| 2019 Q1 | 512.16 Thousand USD | -84.33% |
| 2019 FY | 20.34 Million USD | -4.08% |
| 2019 Q4 | 1.7 Million USD | -2.8% |
| 2019 Q2 | 2.26 Million USD | 342.55% |
| 2018 Q2 | 3.82 Million USD | 97.48% |
| 2018 Q1 | 1.93 Million USD | 19.42% |
| 2018 FY | 21.2 Million USD | 15.17% |
| 2018 Q4 | 3.26 Million USD | 38.8% |
| 2018 Q3 | 2.35 Million USD | -38.36% |
| 2017 Q4 | 1.61 Million USD | -33.82% |
| 2017 FY | 18.41 Million USD | -8.48% |
| 2017 Q3 | 2.44 Million USD | 26.17% |
| 2017 Q2 | 1.94 Million USD | -62.86% |
| 2017 Q1 | 5.22 Million USD | -3.46% |
| 2016 Q4 | 5.41 Million USD | -15.19% |
| 2016 Q2 | 4.45 Million USD | -20.5% |
| 2016 FY | 20.12 Million USD | -3.79% |
| 2016 Q1 | 5.6 Million USD | 4.37% |
| 2016 Q3 | 6.38 Million USD | 43.19% |
| 2015 Q4 | 5.37 Million USD | 31.49% |
| 2015 Q3 | 4.08 Million USD | -25.13% |
| 2015 Q2 | 5.45 Million USD | -19.21% |
| 2015 Q1 | 6.75 Million USD | 9.17% |
| 2015 FY | 20.91 Million USD | -15.48% |
| 2014 Q3 | 6.67 Million USD | 1.77% |
| 2014 Q4 | 6.18 Million USD | -7.32% |
| 2014 FY | 24.74 Million USD | 215.78% |
| 2014 Q2 | 6.55 Million USD | 23.2% |
| 2014 Q1 | 5.32 Million USD | 54.27% |
| 2013 Q1 | 611.6 Thousand USD | -92.43% |
| 2013 Q3 | 4.17 Million USD | 931.77% |
| 2013 Q4 | 3.45 Million USD | -17.4% |
| 2013 FY | 7.83 Million USD | -70.16% |
| 2013 Q2 | 404.96 Thousand USD | -33.79% |
| 2012 Q4 | 8.07 Million USD | 0.0% |
| 2012 FY | 26.26 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 91.496% |
| Dynavax Technologies Corporation | 219.14 Million USD | 90.403% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 96.025% |
| Perrigo Company plc | 1.52 Billion USD | 98.624% |
| Illumina, Inc. | 3.81 Billion USD | 99.448% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 99.795% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 95.337% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.948% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 98.976% |
| Heron Therapeutics, Inc. | 120.65 Million USD | 82.57% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 99.253% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 52.917% |
| Waters Corporation | 943.51 Million USD | 97.771% |
| Biogen Inc. | 5.2 Billion USD | 99.596% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 90.804% |
| Evolus, Inc. | 189.75 Million USD | 88.917% |
| Adicet Bio, Inc. | 152.03 Million USD | 86.168% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 85.238% |
| bluebird bio, Inc. | 240.23 Million USD | 91.246% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 92.265% |
| FibroGen, Inc. | 398.11 Million USD | 94.717% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 99.006% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -51.193% |
| Homology Medicines, Inc. | 9.87 Million USD | -112.966% |
| Geron Corporation | 70.44 Million USD | 70.145% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 98.832% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 95.082% |
| Myriad Genetics, Inc. | 600.1 Million USD | 96.496% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 79.142% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 96.187% |
| Zoetis Inc. | 2.76 Billion USD | 99.239% |
| Abeona Therapeutics Inc. | 48.5 Million USD | 56.64% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 98.07% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.796% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.56% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 46.287% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 97.302% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 92.372% |
| Verastem, Inc. | 92.08 Million USD | 77.162% |
| Nektar Therapeutics | 190.9 Million USD | 88.984% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 95.585% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -73.218% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 98.455% |
| OPKO Health, Inc. | 574.68 Million USD | 96.341% |
| Exelixis, Inc. | 1.58 Billion USD | 98.675% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 98.683% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 94.295% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 62.281% |
| uniQure N.V. | 285.08 Million USD | 92.623% |
| Blueprint Medicines Corporation | 722.86 Million USD | 97.091% |
| Insmed Incorporated | 949.26 Million USD | 97.785% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 92.974% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 94.856% |
| TG Therapeutics, Inc. | 198.47 Million USD | 89.404% |
| Incyte Corporation | 1.19 Billion USD | 98.233% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 97.986% |